{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 69,
        "end": 72
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 75,
        "end": 81
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 112,
        "end": 115
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 147,
        "end": 152
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 184,
        "end": 187
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 69,
        "end": 83
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "23258095_8",
  "text": "CONCLUSIONS : Maintenance therapy with the use of long-term low-dose PEG - IFNa-2 a is effective for preventing HCC occurrence irrespective of the IL28B SNP , at least for a subset of CHC patients ."
}
